Search Within

Hamza Hashmi

Formats
  1. Meeting Abstract (41)
  2. Journal Article (14)
  3. Research Letter (3)
  4. Correspondence (2)
  5. Review (2)
  6. Editorial (1)
Groups
  1. Hematologic Malignancies, Division of (31)
  2. Center for Hematologic Malignancies (30)
  3. Department of Medicine (30)
  4. Bone Marrow Transplant (29)
  5. Survivorship Research (29)
  6. Myeloma (28)

More Groups

People
  1. Saad Usmani (30)
  2. Sridevi Rajeeve (30)
  3. Sham Mailankody (28)
  4. Heather Landau (26)
  5. Alexander Lesokhin (25)
  6. Carlyn Rose Tan (25)

More People

Years
  1. 2025 (11)
  2. 2024 (52)
Publications
  1. Blood (29)
  2. Clinical Lymphoma, Myeloma and Leukemia (16)
  3. Blood Cancer Journal (4)
  4. Blood Advances (3)
  5. European Journal of Haematology (2)
  6. Transplantation and Cellular Therapy (2)

More Publications

Publishers
  1. American Society of Hematology (32)
  2. Elsevier Inc. (18)
  3. Nature Publishing Group (4)
  4. John Wiley & Sons (3)
  5. American Society of Clinical Oncology (1)
  6. Biomed Central Ltd (1)

More Publishers

Results (63)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Absolute lymphocyte count at Day 30 (not earlier) and early CRS predict delayed responses to teclistamab: Results from the US Myeloma Immunotherapy Consortium
    Meeting Abstract

    Banerjee, R.; Kaur, G.; Razzo, B.; Portuguese, A.; Sidana, S.; Richards, T.; Grajales-Cruz, A.; Richard, S.; Shune, L.; Khouri, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; GarceĢs, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis
    Journal Article

    Goel, U.; Dima, D.; Davis, J.; Ahmed, N.; Shaikh, H.; Lochner, J.; Abdallah, A. O.; Khouri, J.; Hashmi, H.; Anwer, F.
    European Journal of Haematology (2024)

    Fulltext@MSK | Save
  • A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection
    Review

    Dietz, L.; Marini, J.; Hashmi, H.; McGann, M.
    Journal of Oncology Pharmacy Practice (2024)

    Fulltext@MSK | Save
  • Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis
    Correspondence

    Epperla, N.; Hashmi, H.; Ahn, K. W.; Allbee-Johnson, M.; Chen, A. I.; Wirk, B.; Kanakry, J. A.; Lekakis, L.; Kharfan-Dabaja, M. A.; Scordo, M.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • TACTUM: Trends in access to cellular therapies in multiple myeloma, perspectives of treating versus referring physicians
    Journal Article

    Atallah, R.; Ahmed, N.; Ayoobkhan, F.; Saif, M. S. I.; Logan, E.; Shrestha, A.; Anwer, F.; Mahmoudjafari, Z.; Mushtaq, M. U.; Hashmi, H.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • "Fast but not so furious": A condensed step-up dosing schedule of teclistamab for relapsed/refractory multiple myeloma
    Journal Article

    Graf, K. C.; Davis, J. A.; Cendagorta, A.; Granger, K.; Gaffney, K. J.; Green, K.; Hess, B. T.; Hashmi, H.
    eJHaem (2024)

    Fulltext@MSK | Save
  • Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
    Journal Article

    Zanwar, S.; Sidana, S.; Shune, L.; Puglianini, O. C.; Pasvolsky, O.; Gonzalez, R.; Dima, D.; Afrough, A.; Kaur, G.; Davis, J. A.; more...
    Journal of Hematology & Oncology (2024)

    Fulltext@MSK | Save
  • Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy
    Journal Article

    Dima, D.; Abdallah, A. O.; Davis, J. A.; Awada, H.; Goel, U.; Rashid, A.; DeJarnette, S.; Anwer, F.; Shune, L.; Raza, S.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save